Abstract
BackgroundBispecific T-cell engagers (TCEs) activate the immune system to Figureht cancer. TCEs that target peptides displayed on major histocompatibility complexes (pMHC) have shown promise for unlocking previously inaccessible intracellular tumor-specific...
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have